Patients tell all: Using a direct-to-patient community registry to understand patient burden of COVID-19
Emma Brinkley(IQVIA (United States)), Nancy A Dreyer(IQVIA (United Kingdom)), Anne-Marie Bourke, Margaret Reynolds(Association of British Insurers), Kalyani Hawaldar(IQVIA (United States)), Christina Mack(University of North Carolina at Chapel Hill), Natalia Petruski‐Ivleva(AVEO Oncology (United States))
Pharmacoepidemiology and Drug Safety
January 1, 2021
Cited by 0
Related Papers
Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study
|Journal of Renal Nutrition|2017|254
Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies
|PLoS Biology|2021|215
Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms
|Pharmacoepidemiology and Drug Safety|2020|120
Admission cardiotocography: a randomised controlled trial
|The Lancet|2003|99
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
|Annals of the Rheumatic Diseases|2023|95